The latest NCCN version on Genetic/Familial High-Risk Assessment (version 1.2024—9 Spetember 2024 https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1544) [39] predicted an up to 43% cumulative lifetime risk of metachronous CRC for MLH1 and MSH2 carriers who have segmental resection, and a lower risk for MSH6 carriers. Here, MSH2 is linked to colorectal carcinoma.